No Heart Risk in Osteoporosis Drugs For Now, FDA Says

WASHINGTON, D.C. - The FDA says it will spend the coming year taking a closer look at bisphosphonate osteoporosis drugs such as Fosamax to determine whether they pose a risk of atrial fibrillation in patients who take them.

FDA made the announcement Oct. 1 after an initial review of safety data it requested in the wake of a May 3 article published in The New England Journal of Medicine. The article described rates of serious atrial fibrillation in two studies of older women treated with bisphosphonates.

According to the FDA, the studies showed that more woman who received either Fosamax …